2 completed, 1 enrolling by invitation, 1 suspended, 1 withdrawn. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Enrolling by invitation 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow tapinarof: new trials by email Literature Review of tapinarof trials Research Report on tapinarof
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis Tapinarof cream, 1%, Vehicle Cream - Atopic Dermatitis | Phase 3 | Suspended | Organon and Co | 187 | 2025-12-29 | 2026-10-05 |
| Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) Betamethasone dipropionate 0.05%, Tapinarof - ICD10 Code L40.9 for Psoriasis | Phase 2 / Phase 3 | Enrolling by invitation | Wake Forest University Health Sciences | 40 | 2024-07-15 | 2026-08-04 |
| Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Tapinarof, Vehicle Cream - Plaque Psoriasis | Phase 3 | Completed | Organon and Co | 515 | 2019-06-06 | 2025-06-12 |
| Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Tapinarof, Vehicle Cream - Plaque Psoriasis | Phase 3 | Completed | Organon and Co | 510 | 2019-05-21 | 2025-06-12 |
| GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis GSK2894512 1% cream, Vehicle cream - Psoriasis | Phase 3 | Withdrawn | GlaxoSmithKline | 2018-01-22 | 2017-12-07 |
Psoriasis (3) · Dermatitis, Atopic (1) · Eczema (1)
Organon and Co (3) · GlaxoSmithKline (1) · Wake Forest University Health Sciences (1)
United States (4) · Canada (3)
Victoria Butners (2) · Steven R Feldman, MD, PhD (1)
PMID 37076998, PMID 37697121, PMID 38123875, PMID 40600584, PMID 34879448